Lutherville, MD, United States of America

Elizabeth Marion Jaffee

This inventor holds 6 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Johns Hopkins University. Active years: 1999-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elizabeth Marion Jaffee. Retrieved from https://idiyas.com/inventor/elizabeth-marion-jaffee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 122(Granted Patents)


Company Filing History:


Years Active: 1999-2020

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Elizabeth Marion Jaffee

Introduction

Elizabeth Marion Jaffee is a prominent inventor based in Lutherville, MD (US). She has made significant contributions to the field of cancer research, holding a total of six patents. Her work focuses on immunological targets that have the potential to revolutionize cancer treatment.

Latest Patents

Among her latest patents is the development of Galectin-3 as an immunological target. This innovation includes compositions for the treatment of cancer that utilize an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor cell vaccine and an anti-galectin-antibody. Increased titers of anti-galectin-antibodies have been correlated with improved clinical outcomes. Another significant patent involves Annexin A2 as an immunological target. Annexin A2 (ANXA2) is a member of the Annexin family of calcium-dependent, phospholipid-binding proteins. It has been identified as an antigen recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. Annexin A2 is abundantly expressed in pancreatic adenocarcinomas, and its expression increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The translocation of Annexin A2 from the cytoplasm to the cell surface is critical for pancreatic cancer cell invasion. Furthermore, the phosphorylation of Annexin A2 at Tyrosine 23 is essential for its localization to the cell surface and for the invasion of pancreatic cancer cells. The loss of Annexin A2 results in the loss of the Epithelial-Mesenchymal Transition.

Career Highlights

Elizabeth Jaffee is affiliated with The Johns Hopkins University, where she continues her groundbreaking research. Her work has garnered attention and respect in the scientific community, contributing to advancements in cancer immunotherapy.

Collaborations

She has collaborated with notable colleagues, including Drew M Pardoll and Hyam I Levitsky, further enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Elizabeth Marion Jaffee's innovative work in cancer research and her numerous patents highlight her significant contributions to the field. Her dedication to improving cancer treatment through immunological targets is paving the way for future advancements in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…